Since development of multiple primary tumors in an individual is a sign of hereditary cancer we utilized a population-based cancer registry to identify women who had developed breast cancer and colorectal cancer in order to assess the contribution of the CHEK2 1100delC mutation to the development of metachronous cancers of these types. Here, CHEK2 is linked to breast carcinoma.